Epithelial Thickness Map

NCT ID: NCT04578184

Last Updated: 2020-10-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-15

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In keratoconic eyes, the corneal epithelium shows a localized thinning over the cone that is surrounded by an annulus of epithelial thickening. It has been postulated that epithelial thickness mapping can be a sensitive tool for the keratoconus diagnosis. In keratoconus screening the 5 mm diameter of the corneal centrum may be sufficient while studies have shown that the cone apex is located in this area.

Aim of this study is to assess agreement and repeatability of epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.

Secondary objective is to evaluate the differences between healthy and keratoconus eyes using epithelial thickness map data.

This is a prospective monocentric study that includes patients divided into two groups: patients with keratoconus and a control group formed out of patients without corneal pathologies. For each patient only one eye will be included and corneal measurements will be performed, focused on the corneal epithelium thickness.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In total 50 eyes of 50 patients will be included, divided into two groups: study group comprised of 20 eyes with diagnosed keratoconus and a control group formed out of 30 healthy eyes.

Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation. After each measurement patients will be asked to blink in order to allow adequate tear-film recovery. Each patient will be measured three times with both devices. Only one visit will be necessary.

The order in which the measurements will be performed (Anterion or MS-39) will be randomised using randomised.org.

The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.

Main outcome variable:

\- Mean differences in central corneal epithelial thickness between the devices investigated (+ limits of agreement (1.96xSD) between the investigated devices)

Secondary outcome variables:

* Repeatability coefficient (within subject standard deviation - SD) and coefficient of variation of the two devices
* Comparison in epithelial thickness between normal and keratoconus eyes
* Sensitivity and specificity of swept-source OCT device in keratoconus diagnosis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keratoconus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Epithelial thickness map evaluation in keratoconus patients

Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.

Group Type OTHER

Corneal epithelial thickness measurements

Intervention Type DIAGNOSTIC_TEST

Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.

Epithelial thickness map evaluation in healthy cornea patients

Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.

Group Type OTHER

Corneal epithelial thickness measurements

Intervention Type DIAGNOSTIC_TEST

Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Corneal epithelial thickness measurements

Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with diagnosed keratoconus (diagnosed using tomography and topography map changes and slit-lamp changes) and patients with healthy cornea
* Age 21 and older
* Signed informed consent

Exclusion Criteria

* Previous ocular surgery
* Associated corneal pathologies (e.g. trauma, edema, scarring)
* In women of childbearing age, a pregnancy test will be performed before inclusion into the study.
Minimum Eligible Age

21 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vienna Institute for Research in Ocular Surgery

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prim. Prof. Dr. Oliver Findl, MBA

Head of Department of Ophthalmology, Professor, Principal Investigator, MBA

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Oliver Findl, Prof., MD

Role: PRINCIPAL_INVESTIGATOR

Head of Department of Ophthalmology, Professor, Principal Investigator

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hanusch Hospital, Ophthalmology Department

Vienna, , Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Oliver Findl, Prof., MD

Role: CONTACT

+43 1 91021-84611

Nino Hirnschall, MD, PhD

Role: CONTACT

+43 1 91021 57564

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Oliver Findl, Prof. MD

Role: primary

+43 1 91021 57564

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Epithelial thickness map

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.